Strikingly, the phase I/II trial involving 72 patients with refractory MM, no patients developed severe peripheral neuropathy when using tanespimycin (17-allylamino-17-demethoxygeldanamycin: 17-AAG) in combination with bortezomib, indicating that HIF-1 inhibitors in combination with conventional anticancer therapy could reduce the therapy-induced pain and enhance the treatment efficacy [166]. This evidence concerns the gene HIF1A and Miyoshi myopathy.